Our innovative DNA-based biomarker identification methods will enable us to mass-produce PCR cancer tests that achieve an industry-leading
95% accuracy rate in tissue biopsy and over 70% in early patient blood samples.
Epi One scientists have a deep understanding of regulating factors behind gene expression. Combining cutting-edge, high-throughput cancer diagnosis methods with our self-developed computational algorithms, we need fewer than 10 genes for diagnosis and prognosis, and can identify highly accurate biomarkers for both tumor-specific and multiple-cancer diagnosis, prognosis, and companion diagnosis.
Now compare that to current cancer screening methodologies. For some tumor types, such as prostate cancer, there is a high false negative rate in the gold standard cancer diagnostic method. And for others, like pancreatic cancer, early diagnosis does not even exist.
Epi One’s DNA-based cancer diagnosis methods change that, providing accurate results in just six hours. Our goal is to make this test ubiquitous at a cost of just $500 per patient, providing highly accurate biomarkers initially for prostate cancer with plans to expand into lung, pancreatic, and other cancers.
Our assay is mass-producible, and is faster and cheaper than sequencing-based technology.
Highly
Accurate
Simple
PCR test
<10 Biomarkers
per test
$500 per
Patient
6 Hour
Turnaround
Interested in Learning More?